An Official Website of the United States Government
Company Information:
Name:
RADIX PHARMACEUTICALS, INC.
Address:
13303 Sunny Brooke Place
Room 101
Potomac, MD 20854-
Room 101
Potomac, MD 20854-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Synthesis and Evaluation of Novel Antimalarial Agents
Award Year / Program / Phase:
2005 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Shuren Zhu
Award Amount:
$100,000.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this research is to develop drugs that are safe and effective against drug-resistant malaria. Malaria is one of the most common infectious diseases in the world. It affects approximately 300 million people and leads to more than 2 million… More
Pre-Clinical Development of Natural Product Analogues as Antimalarial Agents
Award Year / Program / Phase:
2006 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Shuren Zhu
Award Amount:
$604,800.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. SBIR Phase I research and additional work at Radix Pharmaceuticals have… More
Development of Natural Product as Antimalarial Agent
Award Year / Program / Phase:
2007 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Shuren Zhu
Award Amount:
$299,880.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. Radix Pharmaceuticals has isolated an
d purified two natural products from the… More
Isolation and Antimalarial Activity of Small Molecules from Ocimum sanctum
Award Year / Program / Phase:
2008 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Shuren Zhu
Award Amount:
$600,000.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. Radix Pharmaceuticals has isolated an
d purified two natural products from the… More
Pre-Clinical Evaluation of Antimalarial Natural Products from Carica papaya L.
Award Year / Program / Phase:
2008 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Shuren Zhu
Award Amount:
$590,628.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. Radix Pharmaceuticals has isolated an
d purified two natural products from the… More
Preclinical Studies of Natural Product Derivatives as Antimalarial Agents
Award Year / Program / Phase:
2011 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Shuren Zhu – 301-675-3714
Award Amount:
$998,181.00
Abstract:
DESCRIPTION (provided by applicant): This project focuses on the development of a novel therapeutic agent for preventing and treating P. falciparum malaria. A two-year Phase I research has discovered novel molecules with potent antimalarial activity against both sensitive and resistant malaria… More
Development of Small Molecules as Antiprotozoal Agents
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Shuren Zhu – 301-675-3714
Award Amount:
$1,240,336.00
Abstract:
DESCRIPTION (provided by applicant): The proposed research focuses on the development of novel therapeutic agents for the prevention and treatment of malaria caused by P. falciparum. A previous Phase I project has discovered novel molecules with potent antimalarial activity against both sensitive… More